SIGNIFICANTLY DIFFERENT IMMUNE MICROENVIRONMENT BETWEEN TRIPLE-NEGATIVE BREAST CANCER WITH AND WITHOUT NEOADJUVANT CHEMOTHERAPY THROUGH MULTIPLEX IMMUNOHISTOCHEMISTRY

被引：0
|
作者：
Lee, Miseon [1 ]
Lee, Hyun [2 ]
Gong, Gyungyub [3 ]
Lee, Hee Jin [3 ]
机构：
[1] Seoul St Marys Hosp, Coll Med, Seoul, South Korea
[2] NeogenTC Corp, Gyeonggi Do, Hanam Si, South Korea
[3] Univ Ulsan, Coll Med, Seoul, South Korea
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0963
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
963
引用
收藏
页码：A1004 / A1004
页数：1
相关论文
共 50 条
  • [41] BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Nishimiya, Hiroshi
    Tanaka, Youko
    Minatani, Naoko
    Kikuchi, Mariko
    Shida, Akiko
    Waraya, Mina
    Katoh, Hiroshi
    Enomoto, Takumo
    Sengoku, Norihiko
    Kajita, Sabine
    Hoffman, Robert M.
    Watanabe, Masahiko
    PLOS ONE, 2016, 11 (12):
  • [42] BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Sengoku, Norihiko
    Waraya, Mina
    Nishimiya, Hiroshi
    Katoh, Hirozhi
    Kikuchi, Mariko
    Minatani, Naoko
    Teraoka, Saeko
    Enomoto, Takumo
    Sato, Takeo
    Masahiko, Masahiko
    CANCER RESEARCH, 2015, 75
  • [43] Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum
    Dent, Rebecca
    LANCET ONCOLOGY, 2021, 22 (01): : 27 - 28
  • [44] THE GENE EXPRESSION PROFILE OF TRIPLE-NEGATIVE BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPY
    Philipovskiy, A.
    Gaur, S.
    Chambers, K.
    Gamez, R.
    McCallum, R.
    Kirken, R.
    Aguilera, R.
    Roy, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (02) : 440 - 440
  • [45] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
    Nakano, E.
    Hojo, T.
    Masumura, K.
    Kikuyama, M.
    Akashi, S.
    Kinoshita, T.
    CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
  • [46] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [47] Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer
    Di Leone, A.
    Fragomeni, S. M.
    Scardina, L.
    Ionta, L.
    Mule, A.
    Magno, S.
    Terribile, D.
    Masetti, R.
    Franceschini, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (04) : 1910 - 1915
  • [48] Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
    Takayuki Ueno
    Shigehisa Kitano
    Norikazu Masuda
    Daiki Ikarashi
    Makiko Yamashita
    Tomohiro Chiba
    Takayuki Kadoya
    Hiroko Bando
    Takashi Yamanaka
    Shoichiro Ohtani
    Shigenori Nagai
    Takahiro Nakayama
    Masato Takahashi
    Shigehira Saji
    Kenjiro Aogi
    Ravi Velaga
    Kosuke Kawaguchi
    Satoshi Morita
    Hironori Haga
    Shinji Ohno
    Masakazu Toi
    BMC Medicine, 20
  • [49] Residual cancer burden and neoangiogenesis after neoadjuvant chemotherapy in triple-negative breast cancer
    Miyashita, M.
    Sasano, H.
    Tamaki, K.
    Hirakawa, H.
    Ishida, T.
    Ohuchi, N.
    BREAST, 2017, 32 : S100 - S101
  • [50] Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
    Ueno, Takayuki
    Kitano, Shigehisa
    Masuda, Norikazu
    Ikarashi, Daiki
    Yamashita, Makiko
    Chiba, Tomohiro
    Kadoya, Takayuki
    Bando, Hiroko
    Yamanaka, Takashi
    Ohtani, Shoichiro
    Nagai, Shigenori
    Nakayama, Takahiro
    Takahashi, Masato
    Saji, Shigehira
    Aogi, Kenjiro
    Velaga, Ravi
    Kawaguchi, Kosuke
    Morita, Satoshi
    Haga, Hironori
    Ohno, Shinji
    Toi, Masakazu
    BMC MEDICINE, 2022, 20 (01)
12345